key: cord-0909914-5mbr4a4c authors: Leisman, Daniel E.; Mehta, Arnav; Li, Yijia; Kays, Kyle R.; Li, Jonathan Z.; Filbin, Michael R.; Goldberg, Marcia B. title: Vasopressin infusion in COVID-19 critical illness is not associated with impaired viral clearance: a pilot study date: 2021-07-20 journal: Br J Anaesth DOI: 10.1016/j.bja.2021.07.005 sha: 6bb151cb42728c1e6d8b37688ed105678862c823 doc_id: 909914 cord_uid: 5mbr4a4c nan Editor -COVID-19 can progress rapidly to hypoxaemic respiratory failure and acute respiratory distress syndrome (ARDS) requiring invasive mechanical ventilation. Current guidelines recommend treating these patients with lung protective ventilation, which has a proven survival benefit in ARDS. 1 Additional strategies employed frequently in cases of severe hypoxaemia are pharmacologic paralysis and prone positioning. 2 These interventions all require heavy sedation, which in turn necessitates circulatory support with vasopressor medications. Vasopressin, a vasopressin-receptor agonist, is one such medication. Vasopressin infusion reduces total norepinephrine-equivalent dose requirements and may be renal function-sparing. 3 Literature also suggests vasopressin's vasoconstrictive effects spare the pulmonary vasculature. 4, 5 This is in contrast to catecholamine alternatives, such as norepinephrine, which increase both systemic and pulmonary vascular resistance. 5 Patients with COVID-19 respiratory failure are thought to experience significant hypoxic pulmonary vasoconstriction, which in turn increases right ventricular afterload. Some propose vasopressin produces less right heart strain than catecholamine alternatives. For these reasons, vasopressin is commonly employed in COVID-19 respiratory failure. However, recent preclinical data show that molecular complexes form between the SARS-CoV-2 spike protein, soluble angiotensin-converting enzyme-2 (sACE-2), and vasopressin. 6 These complexes facilitate cellular infection through vasopressin receptor-1b-mediated endocytosis. 6 We previously showed that persistent viraemia was a feature of COVID-19 critical illness and associated with illness severity and worse outcomes. 7 Therefore, we tested the hypothesis that vasopressin treatment could promote cellular infection and systemic viral dissemination. We conducted an IRB-approved post hoc analysis of a prospective observational cohort of patients, described in previously, 6 who presented to Massachusetts General Hospital from March 24-April 30, 2020. We analysed 52 patients intubated on the day of hospital presentation who had a blood sample drawn for proteomic analysis and viral mRNA measurement at least twice among hospital Days 0, 3, and 7. Plasma sACE-2 levels were measured by O-link proximity extension assay. 6 Viral mRNA, measured as described, 7 is a semi-quantitative measurement. The assay reports continuous quantifiable values above 2.00 log10-copies mL -1 , detectable but unquantifiable levels below 2.00 log10-copies mL -1 , or undetectable levels. In this study, we encoded detectable viral mRNA levels below the quantification limit as '1.00', and undetectable mRNA as '0' log10-copies mL -1 . The primary response variable was Day 3 viral mRNA level, adjusted for Day 0 mRNA level in multivariable linear regression. We also compared Day 7 mRNA levels in this manner. We compared patients who received >1 h of vasopressin before Day 3 vs. those who did not. Standard practice was to administer vasopressin at only one rate (0.04 units min -1 ). Additional outcomes were sACE-2 levels, and the number of patients with viral "clearance" between vasopressin-treated and untreated groups. Clearance was defined as undetectable viraemia by Day 7. Previously viraemic patients who died on or before Day 7 and before a subsequent viral mRNA measurement were considered to not have viral clearance. Sensitivity analysis confirmed that recoding patients who died before Day 7 as having clearance did not change results. Viral clearance was analysed with Wald 95% confidence intervals and Fisher's exact test. To assess the association between the total duration of vasopressin exposure with viral mRNA and sACE-2, we applied multivariable linear regression as above. All patients (n=52) had blood collection at baseline (Day 0) and all were viraemic (eTable-1). Of these, 24 (46%) received vasopressin i.v. infusion before Day 3 with median treatment duration 33 h (interquartile range: 12-64). Vasopressin treatment was not associated with higher viral mRNA level vs. non-treatment at Day 3 (difference=0.24 log10-copies mL In this series of 52 critically ill patients with COVID-19 in hypoxaemic respiratory failure, vasopressin infusion was not associated with increased viral mRNA levels or decreased frequency of viral clearance. Vasopressin treatment was also not associated with an increase in sACE-2. While the study is too small to exclude a meaningful effect of vasopressin treatment on viral clearance, the results suggest that vasopressin's in vitro effects on the SARS-CoV-2 lifecycle do not translate to clinically relevant increases in viraemia. This small, single-centre, retrospective study was conducted on samples collected prior to widespread adoption of corticosteroid treatment for severe COVID-19. 8 Immunosuppression could potentiate pro-viral effects of vasopressin to a clinically relevant degree. Corroborating our null findings in patients treated with multimodal immunosuppression is a worthwhile next step. Independent of an effect of vasopressin on SARS-CoV-2 viraemia, our study does not address whether SARS-CoV-2 infection alters the physiologic response to vasopressin. Such effect could be present given that uptake of virus-ACE2-vasopressin complexes occurs via endocytosis, which could decrease vasopressin receptor-1b availability for physiologic signalling. There are no randomised data and no currently registered trials addressing vasopressin treatment in COVID-19. In COVID-19 critical illness, selection of vasopressors to treat hypotension, much of which is likely induced by sedation, will remain without a solid evidence base at least for the short-term. In conclusion, despite preclinical data raising the possibility that vasopressin facilitates SARS-CoV-2 dissemination in vivo, we did not observe evidence of a clinically relevant effect of vasopressin infusion on viral mRNA level in a pilot cohort of critically ill patients with COVID-19 who were not treated with corticosteroids or interleukin-6 antagonists. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) Prone positioning in severe acute respiratory distress syndrome Vasopressin versus norepinephrine infusion in patients with septic shock Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study Vasopressin decreases pulmonaryto-systemic vascular resistance ratio in a porcine model of severe hemorrhagic shock Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis All authors declare no conflicts of interest. The authors declare the following additional funding sources: AM: US National institutes of Health T32 2T32CA071345-21A1 (unrelated to this work). MRF: research grants received from Day Zero Diagnostics, Rapid Pathogen Screening Inc., Nihon Kohden Corporation (all unrelated to this work). MGB: research grants from American Lung Association (COVID-19 Action Initiative), Executive Committee on Research at MGH. All other authors declare no funding or interests.